Department of Surgery, Far Eastern Memorial Hospital, Pan-Chiao, New Taipei, Taiwan, ROC.
Anticancer Res. 2012 Jul;32(7):2991-8.
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a tumor and metastasis suppressor gene, is critical for the regulation of the invasive and metastatic activities of tumor cells. RECK is down-regulated in some malignancies and its expression is positively correlated with survival of patients with cancer. Patients with malignant glioma have poor prognosis. Since RECK expression decreases as the tumor stage progresses from less invasive grade II glioma to invasive glioblastoma multiforme, up-regulation of RECK by natural or synthetic agents might be a valuable therapeutic option for glioma. Histone deacetylase inhibitors and non-steroidal anti-inflammatory drugs have been widely used clinically and demonstrated to increase RECK expression in cancer cells, thus they might be used as RECK inducers. In this article, the functions of RECK and the role of RECK in glioma are reviewed, with emphasis on the potential application of RECK inducers in the treatment of glioma.
富含半胱氨酸的 Kazal 基序的反式诱导蛋白（RECK）是一种肿瘤和转移抑制基因，对肿瘤细胞侵袭和转移活性的调节至关重要。RECK 在一些恶性肿瘤中下调，其表达与癌症患者的生存呈正相关。恶性神经胶质瘤患者预后不良。由于 RECK 的表达随着肿瘤的进展而降低，从侵袭性较低的 II 级神经胶质瘤到侵袭性多形性胶质母细胞瘤，天然或合成剂对 RECK 的上调可能是神经胶质瘤的一种有价值的治疗选择。组蛋白去乙酰化酶抑制剂和非甾体抗炎药已广泛应用于临床，并证明能增加癌细胞中 RECK 的表达，因此它们可能被用作 RECK 诱导剂。本文综述了 RECK 的功能及其在神经胶质瘤中的作用，重点介绍了 RECK 诱导剂在神经胶质瘤治疗中的潜在应用。
